Login to Your Account

Financings Roundup

Telormedix Gets $7M for Bladder Cancer Therapy

By Cormac Sheridan
Staff Writer

Monday, December 2, 2013
Telormedix SA took in CHF6 million (US$6.6 million) in a Series B funding round to enable it to complete an ongoing Phase II study of its lead drug TMX-101 in bladder cancer patients and to begin preparations for a potentially pivotal study in 2014. The cash takes the company’s total equity investment to CHF34.5 million.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription